Project Details
Description
A Phase 2 Evaluation of the Monoclonal Antibody RAV12, in Combination with Standard Gemcitabine in the Treatment of Patients with Metastatic Pancreatic Cancer
| Status | Finished |
|---|---|
| Effective start/end date | 9/3/07 → 10/15/08 |
Funding
- TGEN DRUG DEV SVC (TD2)
- RAVEN BIOTECHNOLOGIES INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.